n(g),n(g')-dimethyl-l-arginine has been researched along with Elevated Cholesterol in 36 studies
N,N-dimethylarginine: asymmetric dimethylarginine; do not confuse with N,N'-dimethylarginine
| Excerpt | Relevance | Reference |
|---|---|---|
| " The aim of the present study is to compare the effects of moderate (40 mg) to high (80 mg) simvastatin doses on asymmetric dimethylarginine and total homocysteine levels in patients with newly detected severe hypercholesterolemia (after target LDL-C levels, ≤2." | 9.15 | Effect of moderate and high-dose simvastatin on asymmetric dimethylarginine-homocysteine metabolic pathways in patients with newly detected severe hypercholesterolemia. ( Deneva, TI; Marinov, B; Vladimirova-Kitova, LG, 2011) |
| " This study compares the effect of moderate (40 mg) to high (80 mg) simvastatin doses on asymmetric dimethylarginine levels in patients with newly detected severe hypercholesterolemia (after targeted LDL levels of < or = 2." | 9.14 | Simvastatin and asymmetric dimethylarginine-homocysteine metabolic pathways in patients with newly detected severe hypercholesterolemia. ( Deneva, TI; Vladimirova-Kitova, LG, 2010) |
| "Little is know about the relationship between asymmetric dimethylarginine (ADMA) and percent flow-mediated dilatation (%FMD) in subjects with severe hypercholesterolemia (HH)." | 7.74 | Relationship of asymmetric dimethylarginine with flow-mediated dilatation in subjects with newly detected severe hypercholesterolemia. ( Angelova, E; Deneva, T; Marinov, B; Mateva, N; Nikolov, F; Vladimirova-Kitova, L, 2008) |
| "Fluvastatin treatment for hypercholesterolemia in patients with MetS is associated with a decrease in serum ADMA levels at 6 weeks." | 6.73 | Short term fluvastatin treatment lowers serum asymmetric dimethylarginine levels in patients with metabolic syndrome. ( Oguz, A; Uzunlulu, M, 2008) |
| " Mechanisms responsible for endothelial dysfunction in hyperhomocyst(e)inemia may involve impaired bioavailability of endothelium-dependent nitric oxide." | 5.31 | Plasma concentration of asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, is elevated in monkeys with hyperhomocyst(e)inemia or hypercholesterolemia. ( Bode-Böger, SM; Böger, RH; Heistad, DD; Lentz, SR; Sydow, K, 2000) |
| " The aim of the present study is to compare the effects of moderate (40 mg) to high (80 mg) simvastatin doses on asymmetric dimethylarginine and total homocysteine levels in patients with newly detected severe hypercholesterolemia (after target LDL-C levels, ≤2." | 5.15 | Effect of moderate and high-dose simvastatin on asymmetric dimethylarginine-homocysteine metabolic pathways in patients with newly detected severe hypercholesterolemia. ( Deneva, TI; Marinov, B; Vladimirova-Kitova, LG, 2011) |
| " This study compares the effect of moderate (40 mg) to high (80 mg) simvastatin doses on asymmetric dimethylarginine levels in patients with newly detected severe hypercholesterolemia (after targeted LDL levels of < or = 2." | 5.14 | Simvastatin and asymmetric dimethylarginine-homocysteine metabolic pathways in patients with newly detected severe hypercholesterolemia. ( Deneva, TI; Vladimirova-Kitova, LG, 2010) |
| "The aim of the present study was to investigate plasma levels of asymmetric dimethylarginine (ADMA), an important endogenous inhibitor of nitric oxide synthase, in populations at high risk for atherosclerosis as compared to healthy controls, and furthermore to evaluate the effect of cholesterol lowering therapy in individuals with hypercholesterolemia." | 5.10 | Increased levels of asymmetric dimethylarginine in populations at risk for atherosclerotic disease. Effects of pravastatin. ( Arnesen, H; Eid, HM; Eritsland, J; Larsen, J; Seljeflot, I, 2003) |
| "Asymmetric dimethylarginine (ADMA) is a competitive endogenous inhibitor of nitric oxide synthase with a key role in the pathophysiology of endothelial dysfunction, in the progression of atherosclerosis and in cardiovascular diseases." | 4.91 | Asymmetric Dimethylarginine: Clinical Significance and Novel Therapeutic Approaches. ( Georgakis, MK; Latsios, G; Oikonomou, E; Papageorgiou, N; Papaioannou, S; Siasos, G; Tousoulis, D; Zaromitidou, M, 2015) |
| "Hypercholesterolemia is characterized by changes in lipid profile, nitric oxide pathway, and oxidative stress markers, but functions of high-density lipoprotein (HDL) were not well established in hypercholesterolemic subjects treated with atorvastatin." | 3.81 | The effects of atorvastatin on antioxidant/antiinflammatory properties of HDLs in hypercholesterolemics. ( Akalin Çiftçi, G; Akalin, A; Alataş, İÖ; Ertorun, İ; Musmul, A, 2015) |
| "We examined the flow-mediated arterial diastolic function (FMD), the levels of IGF-1, asymmetric dimethylarginine (ADMA), NO, and the activity of nitric oxide synthase (NOS) in the serum from 25 patients with hypercholesterolemia and from healthy controls." | 3.79 | [Protective effect of insulin-like growth factor-1 on vascular endothelial function in hypercholesterolemia and the underlying mechanism]. ( Ji, S; Luo, X; Ma, Q; Peng, J, 2013) |
| "A low concentration of nitric oxide associated with a high concentration of asymmetric dimethylarginine (ADMA) can explain the lack of ischemic cardioprotection observed in the presence of hypercholesterolemia." | 3.79 | High plasma concentrations of asymmetric dimethylarginine inhibit ischemic cardioprotection in hypercholesterolemic rats. ( Casella-Filho, A; Chagas, AC; da-Luz, PL; Dourado, PM; Landim, MB, 2013) |
| "This research is aimed at studying the predictors of the IMT of CCA among basic atherogenic risk biomarkers - lipid [total cholesterol (TC), triglycerides, high-density lipoprotein cholesterol, low-density lipoprotein (LDL) cholesterol, Apolipoprotein-B, Apolipoprotein-Ai, Apolipoprotein-B/A(1) index] and non-lipid, [asymmetric dimethylarginine (ADMA), total homocysteine, cell adhesion molecules] in asymptomatic subjects with newly detected severe hypercholesterolemia." | 3.76 | Predictors of the intima-media thickness of carotid artery in asymptomatic newly detected severe hypercholesterolemic patients. ( Deneva, T; Marinov, B; Vladimirova-Kitova, L, 2010) |
| "Little is know about the relationship between asymmetric dimethylarginine (ADMA) and percent flow-mediated dilatation (%FMD) in subjects with severe hypercholesterolemia (HH)." | 3.74 | Relationship of asymmetric dimethylarginine with flow-mediated dilatation in subjects with newly detected severe hypercholesterolemia. ( Angelova, E; Deneva, T; Marinov, B; Mateva, N; Nikolov, F; Vladimirova-Kitova, L, 2008) |
| "Asymmetric dimethylarginine (ADMA), an endogenous inhibitor of nitric oxide synthase, is elevated in hypercholesterolemia." | 3.70 | Asymmetric dimethylarginine increases mononuclear cell adhesiveness in hypercholesterolemic humans. ( Blaschke, TF; Bode-Böger, SM; Böger, RH; Chan, JR; Cooke, JP; Tangphao, O; Tsao, PS, 2000) |
| " We examined the hypothesis that HC may inhibit ischemia-induced angiogenesis by inhibition of EDNO in a rat model of unilateral hindlimb ischemia and that oral L-arginine supplementation, a substrate for NO synthase, may prevent HC-related impairment of angiogenesis." | 3.70 | Hypercholesterolemia inhibits angiogenesis in response to hindlimb ischemia: nitric oxide-dependent mechanism. ( Duan, J; Ikeda, H; Imaizumi, T; Katoh, A; Kawata, H; Murohara, T; Sasaki, K; Shintani, S; Yamamoto, N, 2000) |
| "Fluvastatin treatment for hypercholesterolemia in patients with MetS is associated with a decrease in serum ADMA levels at 6 weeks." | 2.73 | Short term fluvastatin treatment lowers serum asymmetric dimethylarginine levels in patients with metabolic syndrome. ( Oguz, A; Uzunlulu, M, 2008) |
| "Hypercholesterolemia is linked to endothelial dysfunction and enhancement of the endogenous inhibitor of NO synthase." | 2.71 | Effects of simvastatin and L-arginine on vasodilation, nitric oxide metabolites and endogenous NOS inhibitors in hypercholesterolemic subjects. ( Abdalla, DS; Bersch, D; Bertolami, MC; Faludi, AA; Pereira, EC; Salem, M, 2003) |
| " Potential mechanisms underlying impaired endothelial function and decreased bioavailability of nitric oxide under these clinical conditions are discussed." | 2.42 | Potential mechanisms of impaired endothelial function in arterial hypertension and hypercholesterolemia. ( John, S; Schmieder, RE, 2003) |
| "Insulin sensitivity was impaired only in T2DM." | 1.39 | Roles of insulin, age, and asymmetric dimethylarginine on nitric oxide synthesis in vivo. ( Artusi, C; Cecchet, D; Millioni, R; Plebani, M; Puricelli, L; Tessari, P; Vedovato, M; Vettore, M, 2013) |
| "Homocysteine is a cardiovascular risk factor, its metabolism is influenced by certain B vitamins and it is associated with endothelial dysfunction probably due to impaired bioavailability of NO caused by homocysteine-induced accumulation of asymmetric dimethylarginine (ADMA), an endogenous inhibitor of NO synthase." | 1.37 | Homocysteine and asymmetric dimethylarginine in relation to B vitamins in elderly people. ( Elmadfa, I; Fabian, E; Kickinger, A; Wagner, KH, 2011) |
| "Concerning Alzheimer's disease (AD), there are reports on altered cerebral NO metabolism, but only few studies on ADMA concentrations in plasma and cerebrospinal fluid (CSF)." | 1.35 | Asymmetrical dimethylarginine is increased in plasma and decreased in cerebrospinal fluid of patients with Alzheimer's disease. ( Arlt, S; Böger, RH; Eichenlaub, M; Jahn, H; Lehmbeck, JT; Maas, R; Schulze, F; Schwedhelm, E, 2008) |
| "Hypercholesterolemia is characterized with changes in lipid profile, nitric oxide pathway and oxidative stress markers." | 1.34 | Effects of atorvastatin therapy on hypercholesterolemic rabbits with respect to oxidative stress, nitric oxide pathway and homocysteine. ( Altug, T; Aslan, M; Balci, H; Bolayirli, IM; Hacibekiroglu, M; Seven, A, 2007) |
| "Hindlimb ischemia was surgically induced in C57BL/6J mice, apo E-deficient mice, or transgenic mice overexpressing dimethylarginine dimethylaminohydrolase (DDAH)." | 1.33 | ADMA regulates angiogenesis: genetic and metabolic evidence. ( Achan, V; Cooke, JP; Heeschen, C; Ho, HK; Jang, JJ; Kimoto, M; Stuehlinger, M; Vallance, P, 2005) |
| " Mechanisms responsible for endothelial dysfunction in hyperhomocyst(e)inemia may involve impaired bioavailability of endothelium-dependent nitric oxide." | 1.31 | Plasma concentration of asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, is elevated in monkeys with hyperhomocyst(e)inemia or hypercholesterolemia. ( Bode-Böger, SM; Böger, RH; Heistad, DD; Lentz, SR; Sydow, K, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (5.56) | 18.2507 |
| 2000's | 16 (44.44) | 29.6817 |
| 2010's | 18 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Venkatesh, R | 1 |
| Srinivasan, K | 1 |
| Singh, SA | 1 |
| Rzepecka-Stojko, A | 1 |
| Stojko, J | 1 |
| Jasik, K | 1 |
| Buszman, E | 1 |
| Wielkoszyński, T | 1 |
| Zalejska-Fiolka, J | 1 |
| Strzelczyk, JK | 1 |
| Owczarek, AJ | 1 |
| Cholewka, A | 1 |
| Furmański, M | 1 |
| Stanek, A | 1 |
| Ji, S | 1 |
| Ma, Q | 1 |
| Luo, X | 1 |
| Peng, J | 1 |
| Tessari, P | 1 |
| Cecchet, D | 1 |
| Artusi, C | 1 |
| Vettore, M | 1 |
| Millioni, R | 1 |
| Plebani, M | 1 |
| Puricelli, L | 1 |
| Vedovato, M | 1 |
| Landim, MB | 1 |
| Dourado, PM | 1 |
| Casella-Filho, A | 1 |
| Chagas, AC | 1 |
| da-Luz, PL | 1 |
| Brinkmann, SJ | 1 |
| Wörner, EA | 1 |
| Buijs, N | 1 |
| Richir, M | 1 |
| Cynober, L | 1 |
| van Leeuwen, PA | 1 |
| Couderc, R | 1 |
| İn, E | 1 |
| Özdemir, C | 1 |
| Kaman, D | 1 |
| Sökücü, SN | 1 |
| Akalin Çiftçi, G | 1 |
| Ertorun, İ | 1 |
| Akalin, A | 1 |
| Alataş, İÖ | 1 |
| Musmul, A | 1 |
| Tousoulis, D | 1 |
| Georgakis, MK | 1 |
| Oikonomou, E | 1 |
| Papageorgiou, N | 1 |
| Zaromitidou, M | 1 |
| Latsios, G | 1 |
| Papaioannou, S | 1 |
| Siasos, G | 1 |
| Chen, J | 1 |
| Hamm, LL | 1 |
| Mohler, ER | 1 |
| Hudaihed, A | 1 |
| Arora, R | 1 |
| Chen, CS | 1 |
| Liu, Y | 1 |
| Browne, G | 1 |
| Mills, KT | 1 |
| Kleinpeter, MA | 1 |
| Simon, EE | 1 |
| Rifai, N | 1 |
| Klag, MJ | 1 |
| He, J | 1 |
| Vladimirova-Kitova, LG | 4 |
| Manukov, IH | 1 |
| Sirakova, I | 1 |
| Deneva, TI | 3 |
| Oguz, A | 1 |
| Uzunlulu, M | 1 |
| Arlt, S | 1 |
| Schulze, F | 1 |
| Eichenlaub, M | 1 |
| Maas, R | 2 |
| Lehmbeck, JT | 1 |
| Schwedhelm, E | 3 |
| Jahn, H | 1 |
| Böger, RH | 7 |
| Vladimirova-Kitova, L | 2 |
| Deneva, T | 2 |
| Angelova, E | 1 |
| Nikolov, F | 1 |
| Marinov, B | 3 |
| Mateva, N | 1 |
| Marín, M | 1 |
| Máñez, S | 1 |
| Rossenbach, J | 1 |
| Mueller, GA | 1 |
| Lange, K | 1 |
| Armstrong, VW | 1 |
| Schmitto, JD | 1 |
| Hintze, E | 1 |
| Helfmann, J | 1 |
| Konstantinides, S | 1 |
| Koziolek, MJ | 1 |
| Fabian, E | 1 |
| Kickinger, A | 1 |
| Wagner, KH | 1 |
| Elmadfa, I | 1 |
| Chobanyan-Jürgens, K | 1 |
| Fuchs, AJ | 1 |
| Tsikas, D | 2 |
| Kanzelmeyer, N | 1 |
| Das, AM | 1 |
| Illsinger, S | 1 |
| Vaske, B | 1 |
| Jordan, J | 1 |
| Lücke, T | 1 |
| Eid, HM | 1 |
| Eritsland, J | 1 |
| Larsen, J | 1 |
| Arnesen, H | 1 |
| Seljeflot, I | 1 |
| John, S | 1 |
| Schmieder, RE | 1 |
| Pereira, EC | 1 |
| Bertolami, MC | 1 |
| Faludi, AA | 1 |
| Salem, M | 1 |
| Bersch, D | 1 |
| Abdalla, DS | 1 |
| Bode-Böger, SM | 6 |
| Phivthong-Ngam, L | 1 |
| Frölich, JC | 2 |
| Achan, V | 1 |
| Ho, HK | 1 |
| Heeschen, C | 1 |
| Stuehlinger, M | 1 |
| Jang, JJ | 1 |
| Kimoto, M | 1 |
| Vallance, P | 1 |
| Cooke, JP | 3 |
| Martens-Lobenhoffer, J | 1 |
| Westphal, S | 1 |
| Awiszus, F | 1 |
| Luley, C | 1 |
| Bolayirli, IM | 1 |
| Aslan, M | 1 |
| Balci, H | 1 |
| Altug, T | 1 |
| Hacibekiroglu, M | 1 |
| Seven, A | 1 |
| Kahl, L | 1 |
| Li, H | 1 |
| Benndorf, R | 1 |
| Lüneburg, N | 1 |
| Förstermann, U | 1 |
| Kienke, S | 1 |
| Junker, W | 1 |
| Szuba, A | 1 |
| Tsao, PS | 2 |
| Chan, JR | 2 |
| Tangphao, O | 2 |
| Blaschke, TF | 2 |
| Sydow, K | 1 |
| Heistad, DD | 1 |
| Lentz, SR | 1 |
| Duan, J | 1 |
| Murohara, T | 1 |
| Ikeda, H | 1 |
| Katoh, A | 1 |
| Shintani, S | 1 |
| Sasaki, K | 1 |
| Kawata, H | 1 |
| Yamamoto, N | 1 |
| Imaizumi, T | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of Oral Supplementation With One Form of L-arginine on Vascular Endothelial Function in Healthy Subjects Featuring Risk Factors Related to the Metabolic Syndrome.[NCT02354794] | 36 participants (Actual) | Interventional | 2014-02-28 | Completed | |||
| Characterization of the Metabolic Fate of an Oral L-arginine Form in Healthy Subjects Featuring Risk Factors Related to the Metabolic Syndrome.[NCT02352740] | 32 participants (Actual) | Interventional | 2013-03-31 | Completed | |||
| Adiposity and Airway Inflammation in HIV-Associated Airway Disease[NCT02975258] | 102 participants (Actual) | Observational | 2015-09-30 | Completed | |||
| A Pilot Study of the Effect of Dietary Sodium Intake on Assessments of Vascular Endothelium[NCT01550315] | 27 participants (Actual) | Interventional | 2012-04-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The primary analysis will involve a non-parametric, paired, Signed Rank test of flow mediated dilation (FMD) between all subjects (POTS & control subjects) on the high sodium diet vs low sodium diet (NCT01550315)
Timeframe: FMD was assessed on the morning of day 7, after 6 days of being on either a high salt diet or a low salt diet.
| Intervention | percentage of change (Mean) |
|---|---|
| High Sodium POTS | 12.75 |
| Low Sodium Diet POTS | 11.65 |
| High Sodium Controls | 11.43 |
| Low Sodium Controls | 12.75 |
4 reviews available for n(g),n(g')-dimethyl-l-arginine and Elevated Cholesterol
| Article | Year |
|---|---|
Asymmetric Dimethylarginine: Clinical Significance and Novel Therapeutic Approaches.
Topics: Alzheimer Disease; Animals; Arginine; Cardiovascular Diseases; Diabetes Mellitus; Female; Humans; Hy | 2015 |
Asymmetric dimethylarginine--mechanisms and targets for therapeutic management.
Topics: Angiotensin-Converting Enzyme Inhibitors; Arginine; Endothelium, Vascular; Estrogen Replacement Ther | 2008 |
Pharmacological interventions on asymmetric dimethylarginine, a clinical marker of vascular disease.
Topics: Adrenergic Antagonists; Angiotensins; Arginine; Diabetes Complications; Humans; Hydroxymethylglutary | 2011 |
Potential mechanisms of impaired endothelial function in arterial hypertension and hypercholesterolemia.
Topics: Animals; Arginine; Biological Availability; Cyclic GMP; Endothelium, Vascular; Humans; Hypercholeste | 2003 |
7 trials available for n(g),n(g')-dimethyl-l-arginine and Elevated Cholesterol
| Article | Year |
|---|---|
Interrelationship of Multiple Endothelial Dysfunction Biomarkers with Chronic Kidney Disease.
Topics: Adult; Aged; Albuminuria; Arginine; Biomarkers; Blood Glucose; Cell Adhesion Molecules; Comorbidity; | 2015 |
Short term fluvastatin treatment lowers serum asymmetric dimethylarginine levels in patients with metabolic syndrome.
Topics: Adult; Arginine; Cholesterol; Endothelium, Vascular; Fatty Acids, Monounsaturated; Female; Fluvastat | 2008 |
Effect of moderate and high-dose simvastatin on asymmetric dimethylarginine-homocysteine metabolic pathways in patients with newly detected severe hypercholesterolemia.
Topics: Adult; Arginine; Biomarkers; Bulgaria; Cholesterol, LDL; Chromatography, High Pressure Liquid; Dose- | 2011 |
Simvastatin and asymmetric dimethylarginine-homocysteine metabolic pathways in patients with newly detected severe hypercholesterolemia.
Topics: Adult; Anticholesteremic Agents; Arginine; Dose-Response Relationship, Drug; Enzyme-Linked Immunosor | 2010 |
Increased levels of asymmetric dimethylarginine in populations at risk for atherosclerotic disease. Effects of pravastatin.
Topics: Arginine; Arteriosclerosis; Cholesterol, LDL; Diabetes Mellitus, Type 1; Female; Humans; Hypercholes | 2003 |
Effects of simvastatin and L-arginine on vasodilation, nitric oxide metabolites and endogenous NOS inhibitors in hypercholesterolemic subjects.
Topics: Anticholesteremic Agents; Arginine; Dose-Response Relationship, Drug; Endothelium, Vascular; Female; | 2003 |
Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia.
Topics: Arginine; Double-Blind Method; Endothelium, Vascular; Female; Humans; Hypercholesterolemia; Injectio | 1998 |
Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia.
Topics: Arginine; Double-Blind Method; Endothelium, Vascular; Female; Humans; Hypercholesterolemia; Injectio | 1998 |
Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia.
Topics: Arginine; Double-Blind Method; Endothelium, Vascular; Female; Humans; Hypercholesterolemia; Injectio | 1998 |
Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia.
Topics: Arginine; Double-Blind Method; Endothelium, Vascular; Female; Humans; Hypercholesterolemia; Injectio | 1998 |
25 other studies available for n(g),n(g')-dimethyl-l-arginine and Elevated Cholesterol
| Article | Year |
|---|---|
Effect of arginine:lysine and glycine:methionine intake ratios on dyslipidemia and selected biomarkers implicated in cardiovascular disease: A study with hypercholesterolemic rats.
Topics: Administration, Oral; Amino Acids; Animals; Arginine; Biomarkers; Body Weight; Cardiovascular Diseas | 2017 |
Anti-Atherogenic Activity of Polyphenol-Rich Extract from Bee Pollen.
Topics: Angiotensin II; Animals; Arginine; Atherosclerosis; Bees; Cholesterol; Coronary Artery Disease; Diet | 2017 |
Oxysterols Increase Inflammation, Lipid Marker Levels and Reflect Accelerated Endothelial Dysfunction in Experimental Animals.
Topics: Animals; Arginine; Aryldialkylphosphatase; C-Reactive Protein; Cholesterol; Dyslipidemias; Homocyste | 2018 |
[Protective effect of insulin-like growth factor-1 on vascular endothelial function in hypercholesterolemia and the underlying mechanism].
Topics: Adult; Arginine; Case-Control Studies; Cells, Cultured; Endothelium, Vascular; Female; Human Umbilic | 2013 |
Roles of insulin, age, and asymmetric dimethylarginine on nitric oxide synthesis in vivo.
Topics: Adult; Age Factors; Aged; Arginine; Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; Humans | 2013 |
High plasma concentrations of asymmetric dimethylarginine inhibit ischemic cardioprotection in hypercholesterolemic rats.
Topics: Animals; Arginine; Cholesterol; Cholesterol, Dietary; Disease Models, Animal; Hypercholesterolemia; | 2013 |
The Arginine/ADMA Ratio Is Related to the Prevention of Atherosclerotic Plaques in Hypercholesterolemic Rabbits When Giving a Combined Therapy with Atorvastatine and Arginine.
Topics: Animals; Anticholesteremic Agents; Arginine; Atorvastatin; Cholesterol; Dietary Supplements; Hyperch | 2015 |
Heat Shock Proteins, L-Arginine, and Asymmetric Dimethylarginine Levels in Patients With Obstructive Sleep Apnea Syndrome.
Topics: Adult; Aged; Arginine; Biomarkers; Cardiovascular Diseases; Diabetes Mellitus; Disease Susceptibilit | 2015 |
The effects of atorvastatin on antioxidant/antiinflammatory properties of HDLs in hypercholesterolemics.
Topics: Adult; Anticholesteremic Agents; Arginine; Atorvastatin; Drug Monitoring; Female; Heptanoic Acids; H | 2015 |
Evaluation of the relationship between flow-mediated vasodilation and some atherogenic risk markers in severe hypercholesterolemia.
Topics: Arginine; Atherosclerosis; Biomarkers; Cholesterol, LDL; Humans; Hypercholesterolemia; Risk Factors; | 2008 |
Asymmetrical dimethylarginine is increased in plasma and decreased in cerebrospinal fluid of patients with Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Arginine; Biomarkers; Body Mass Index; Case-Control Studies; Cognition Diso | 2008 |
Relationship of asymmetric dimethylarginine with flow-mediated dilatation in subjects with newly detected severe hypercholesterolemia.
Topics: Adult; Arginine; Biomarkers; Brachial Artery; Case-Control Studies; Endothelium, Vascular; Female; H | 2008 |
Predictors of the intima-media thickness of carotid artery in asymptomatic newly detected severe hypercholesterolemic patients.
Topics: Adult; Age Factors; Arginine; Biomarkers; Bulgaria; Carotid Arteries; Carotid Artery Diseases; Case- | 2010 |
Lipid-apheresis improves microcirculation of the upper limbs.
Topics: Adult; Aged; Arginine; Atrial Natriuretic Factor; Blood Component Removal; Blood Flow Velocity; Endo | 2011 |
Homocysteine and asymmetric dimethylarginine in relation to B vitamins in elderly people.
Topics: Aged; Aged, 80 and over; Arginine; Biological Availability; Endothelium, Vascular; Female; Folic Aci | 2011 |
Increased asymmetric dimethylarginine (ADMA) dimethylaminohydrolase (DDAH) activity in childhood hypercholesterolemia type II.
Topics: Adolescent; Amidohydrolases; Arginine; Case-Control Studies; Child; Female; Humans; Hypercholesterol | 2012 |
Hypercholesterolemia impairs basal nitric oxide synthase turnover rate: a study investigating the conversion of L-[guanidino-(15)N(2)]-arginine to (15)N-labeled nitrate by gas chromatography--mass spectrometry.
Topics: Animals; Arginine; Cholesterol; Cholesterol, Dietary; Diet, Atherogenic; Endothelium, Vascular; Gas | 2004 |
ADMA regulates angiogenesis: genetic and metabolic evidence.
Topics: Animals; Arginine; Blotting, Western; Disease Models, Animal; Female; Hypercholesterolemia; Ischemia | 2005 |
Determination of asymmetric dimethylarginine: liquid chromatography-mass spectrometry or ELISA?
Topics: Arginine; Chromatography, Liquid; Enzyme-Linked Immunosorbent Assay; Humans; Hypercholesterolemia; H | 2005 |
Effects of atorvastatin therapy on hypercholesterolemic rabbits with respect to oxidative stress, nitric oxide pathway and homocysteine.
Topics: Animals; Arginine; Aryldialkylphosphatase; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Diet; H | 2007 |
Simultaneous assessment of endothelial function, nitric oxide synthase activity, nitric oxide-mediated signaling, and oxidative stress in individuals with and without hypercholesterolemia.
Topics: Adolescent; Adult; Aged; Arginine; Cyclic GMP; Dinoprost; Endothelium, Vascular; Female; Humans; Hyp | 2008 |
Simultaneous assessment of endothelial function, nitric oxide synthase activity, nitric oxide-mediated signaling, and oxidative stress in individuals with and without hypercholesterolemia.
Topics: Adolescent; Adult; Aged; Arginine; Cyclic GMP; Dinoprost; Endothelium, Vascular; Female; Humans; Hyp | 2008 |
Simultaneous assessment of endothelial function, nitric oxide synthase activity, nitric oxide-mediated signaling, and oxidative stress in individuals with and without hypercholesterolemia.
Topics: Adolescent; Adult; Aged; Arginine; Cyclic GMP; Dinoprost; Endothelium, Vascular; Female; Humans; Hyp | 2008 |
Simultaneous assessment of endothelial function, nitric oxide synthase activity, nitric oxide-mediated signaling, and oxidative stress in individuals with and without hypercholesterolemia.
Topics: Adolescent; Adult; Aged; Arginine; Cyclic GMP; Dinoprost; Endothelium, Vascular; Female; Humans; Hyp | 2008 |
Elevated L-arginine/dimethylarginine ratio contributes to enhanced systemic NO production by dietary L-arginine in hypercholesterolemic rabbits.
Topics: Arginine; Cholesterol, Dietary; Chromatography, High Pressure Liquid; Diet; Food, Fortified; Hyperch | 1996 |
Asymmetric dimethylarginine increases mononuclear cell adhesiveness in hypercholesterolemic humans.
Topics: Adult; Animals; Aorta; Arginine; Cattle; Cell Adhesion; Chromatography, High Pressure Liquid; Cocult | 2000 |
Plasma concentration of asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, is elevated in monkeys with hyperhomocyst(e)inemia or hypercholesterolemia.
Topics: Animals; Arginine; Cell Line, Transformed; Cholesterol; Diet; Dietary Fats; Endothelium, Vascular; E | 2000 |
Hypercholesterolemia inhibits angiogenesis in response to hindlimb ischemia: nitric oxide-dependent mechanism.
Topics: Administration, Oral; Animals; Arginine; Body Weight; Cholesterol, Dietary; Collateral Circulation; | 2000 |